Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye.
The role of FIB-4 as a simple, cost-effective tool for integrated cardio-hepato-renal risk stratification is supported, and impaired kidney function in patients with MASLD beyond established cardiometabolic risk factors is independently associated with impaired kidney function in patients with MASLD.